Drug Trial Radar · NCT00481871
Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies
Last checked: Nov 20, 2026Latest source record: Jan 7, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
119
Actual
Start
May 2007
Primary completion
May 2011
Study completion Aug 2011
Sponsor
- Lead sponsor
- Acrotech Biopharma Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 4, 2007
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is for patients with lymphoproliferative malignancies that have progressed after receiving a previous treatment (relapsed) or are no longer responding to treatment (refractory). To be in this study, patients must have certain types of Hodgkin's lymphoma (HL), peripheral T-cell lymphoma (PTCL), or B-cell lymphoma, including Waldenstrom's macroglobulinemia. This study is being done to find doses of the combination of pralatrexate and gemcitabine with vitamin B12 and folic acid that can be safely given to patients with these types of lymphoma and explore the effectiveness of the treatment.
Conditions
- Relapsed or Refractory Lymphoproliferative Malignancies
- Hodgkin's Lymphoma
- Peripheral T-cell Lymphoma
- B-cell Lymphoma
- Waldenstrom's Macroglobulinemia
Interventions
Pralatrexate InjectionDrug
Intravenous (IV) push administration over 30 seconds to 5 minutes into a patent IV line containing normal saline (0.9% sodium chloride). Sequential Dosing: 10 mg/m2 every 2 weeks (days 1 and 15) of a 4-week cycle until criteria for discontinuation per the protocol are met. Same Day Dosing: 15 mg/m2 every 2 weeks (days 1 and 15) of a 4-week cycle until criteria for discontinuation per the protocol are met.
Gemcitabine HydrochlorideDrug
Gemcitabine will be prepared and administered as an IV infusion as per manufacturer instructions. Sequential Dosing: 400 mg/m2 every 2 weeks (days 2 and 16) of a 4-week cycle until criteria for discontinuation per the protocol are met. Same Day Dosing: 600 mg/m2 every 2 weeks (days 1 and 15) of a 4-week cycle until criteria for discontinuation per the protocol are met.
Vitamin B12Dietary supplement
1 mg intramuscular injection Administered within 10 weeks of enrollment, every 8-10 weeks throughout the study and for at least 30 days after last dose of pralatrexate.
Folic AcidDietary supplement
1 mg orally Administered daily for at least 7 days prior to start of pralatrexate, throughout the study and for at least 30 days after last dose of pralatrexate.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Responses Assessed by International Workshop Criteria (IWC)Time frame: Assessed every 8 weeks (+/- 1 week) for Phase II and no less than every 3 cycles for Phase I
Locations
15 sites in 1 country. Site status is shown where the registry gives one.
University of California at Los Angeles
Los Angeles, California
Stanford University School of Medicine
Stanford, California
Rocky Mountain Cancer Center
Denver, Colorado
University of Chicago Hospital
Chicago, Illinois
Dana-Farber Cancer Institute
Boston, Massachusetts
Washington University School of Medicine
St Louis, Missouri
University of Nebraska Medical Center
Omaha, Nebraska
The Cancer Center at Hackensack University Medical Center
Hackensack, New Jersey
New York University Hospital
New York, New York
Memorial Sloan-Kettering Cancer Center
New York, New York
Fox Chase Cancer Center
Philadelphia, Pennsylvania
Medical University of South Carolina
Charleston, South Carolina
UT MD Anderson Cancer Center
Houston, Texas
Cancer Therapy & Research Center
San Antonio, Texas
Fred Hutchinson Cancer Research Center
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.